First Turn Management’s Apogee Therapeutics APGE Stock Holding History

First Turn Management’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.4M	Sell	138,822 -374,948	-73%	-$33.8M	1.97%	24
2026 Q1	$43.2M	Buy	513,770 +38,931	+8%	+$2.83M	4.83%	6
2025 Q4	$35.8M	Buy	474,839 +72,028	+18%	+$4.54M	4.1%	9
2025 Q3	$16M	Buy	402,811 +91,321	+29%	+$3.49M	2.4%	20
2025 Q2	$13.5M	Buy	311,490 +81,815	+36%	+$3.11M	2.52%	22
2025 Q1	$8.58M	Sell	229,675 -23,050	-9%	-$891K	1.73%	27
2024 Q4	$11.4M	Buy	+252,725	New	+$12.9M	2.05%	28
2024 Q3	–	Sell	-318,327	Closed	-$12.5M	–	39
2024 Q2	$12.5M	Sell	318,327 -61,476	-16%	-$2.98M	2.04%	27
2024 Q1	$25.2M	Buy	+379,803	New	+$16.6M	3.78%	9

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

First Turn Management's APGE Position: Q2 2026 in Review

First Turn Management reduced its Apogee Therapeutics (APGE) stake by 73% in Q2 2026, selling an estimated $33.8M and leaving 138,822 shares worth $18.4M. The position accounts for 1.97% of the portfolio, ranked #24.

First Turn Management first reported a position in APGE in Q1 2024 and has held it in 9 quarters since. The position peaked at $43.2M in Q1 2026. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

First Turn Management held 138,822 shares of Apogee Therapeutics worth $18.4M as of Q2 2026.
First Turn Management sold 374,948 Apogee Therapeutics shares in Q2 2026, an estimated $33.8M.
Apogee Therapeutics made up 1.97% of First Turn Management's portfolio in Q2 2026, its #24 holding.
First Turn Management first reported a position in Apogee Therapeutics in Q1 2024 and has held it in 9 quarters since.
First Turn Management's Apogee Therapeutics position peaked at $43.2M in Q1 2026.
288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on First Turn Management's 13F filing for Q2 2026, filed 14 Aug 2026.